There are currently 11 active clinical trials seeking participants for Diabetes Mellitus, Type 2 research studies. The states with the highest number of trials for Diabetes Mellitus, Type 2 participants are .
A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473
Recruiting
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 gro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: Pinnacle Research Group, LLC, Anniston, Alabama +1056 locations
Conditions: Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Register for Updates
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
NCT06326047
Recruiting
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/10/2025
Locations: Velocity Clin Res-Chula Vista, Chula Vista, California +114 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
NCT06797869
Recruiting
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: eStudySite, La Mesa, California +49 locations
Conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
Register for Updates
Bone Health After Bariatric Surgery in Patients With Type 2 Diabetes
NCT03455868
Recruiting
Background: Bone fragility is a complication of type 2 diabetes. Diabetes treatments may ameliorate or deteriorate bone fragility in this population. Bariatric surgery is gaining in popularity in people with type 2 diabetes and may impact bone health. Objectives: To evaluate the impact of the most popular bariatric procedure worldwide (sleeve gastrectomy (SG)) on vBMD by QCT in patients with type 2 diabetes; Secondary aims: (1) to identify the determinants of vBMD after bariatric surgery in pati... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/05/2025
Locations: The Research Institute of the McGill University Health Centre, Montréal, Quebec +2 locations
Conditions: Bariatric Surgery, Bone Health, Obesity, Morbid, Diabetes Mellitus, Type 2
Register for Updates
Home-based Heat Therapy for Type 2 Diabetes
NCT05269589
Recruiting
Insulin resistance and hyperglycemia predispose individuals with type 2 diabetes mellitus (T2DM) to endothelial dysfunction and a greater risk of cardiovascular diseases (CVD). Increased CVD risk in individuals with T2DM persists despite optimal pharmacological therapy, highlighting the need to identify complementary lifestyle interventions that improve cardiometabolic functions in this population. Evidence from animal models suggests that heat exposure improves metabolic functions. Notably, wee... Read More
Gender:
ALL
Ages:
Between 45 years and 75 years
Trial Updated:
12/09/2024
Locations: Centre ÉPIC, Montreal Heart Institute, Montréal, Quebec
Conditions: Diabetes Mellitus, Type 2, Heat Exposure
Register for Updates
Metabolic and Inflammatory Outcomes of the Ketogenic Diet Comparing Saturated and Unsaturated Fat Sources
NCT05681468
Recruiting
The goal of this clinical trial is to compare a healthy KETO diet supplemented with canola oil (KETO-Can) compared to a traditional KETO diet high in saturated fat (KETO-Sat) and low-fat diet (LFD) in adults at high risk of or diagnosed with type 2 diabetes. The main question\[s\] it aims to answer are: * Effects on CVD risk factors (plasma cholesterol, TG, ApoB100, glucose, insulin and HbA1C). * Effects on systemic inflammation and immune function. * Adherence to interventions. Participants w... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/26/2024
Locations: University of Alberta, Edmonton, Alberta
Conditions: PreDiabetes, Diabetes Mellitus, Type 2, Overweight and Obesity
Register for Updates
Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II
NCT05702463
Recruiting
This phase 2 study will include patients suffering from type 2 diabetes mellitus and will first study their response to enteric coated aspirin at a dose of 80 mg per day for a 7-day period. Participants with an incomplete platelet inhibition after exposure to EC aspirin at doses of 80 mg once daily will be randomized to a random order of 3 different ASA regimens: EC ASA 162 mg once daily, EC ASA 81 mg twice daily and chewable ASA 40 mg twice daily. The aims are to determine the feasibility of a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: Montreal Heart Institute, Montréal, Quebec
Conditions: Platelet Aggregation, Type 2 Diabetes, Aspirin, Diabetes Mellitus, Type 2, Platelet Aggregation Inhibitors
Register for Updates
Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes
NCT06586203
Recruiting
The goal of this pragmatic trial is to provide Real World Evidence (RWE) on the impact of the result of a polygenic risk prediction test of cardiorenal complications of T2D, so that more patients at high risk of these complications achieve over an 18 months period, recommended therapeutic targets. This will be demonstrated as a significant improvement in a composite value including HbA1c or systolic blood pressure (SBP) or albuminuria (UACR), or glomerular filtration rate (GFR) lowering. Resea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2024
Locations: CHUM, Montreal, Quebec +1 locations
Conditions: Diabetes Mellitus, Type 2, Cardiovascular Diseases, Diabetic Nephropathy Type 2
Register for Updates
Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes
NCT05105919
Recruiting
This phase 1 study will include patients suffering from type 2 diabetes mellitus and will study their response to enteric coated aspirin at a dose of 80 mg per day for a 7-day period. The aims are to determine the feasibility of a phase 2 larger scale trial, and to characterize the prevalence of incomplete platelet inhibition after exposure to EC aspirin at doses of 80 mg once daily. Platelet function will be assessed at baseline and a day 7.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Montreal Heart Institute, Montréal, Quebec
Conditions: Diabetes Mellitus, Type 2
Register for Updates
The Effect of In-utero Exposure to Metformin in 5-11 Year Old Offspring of Mothers in the MiTy Trial
NCT05025852
Recruiting
The incidence of diabetes in pregnancy is rising, with rates of 1 in 7 pregnancies globally. Metformin is used for type 2 diabetes (T2DM) outside of pregnancy and is now increasingly prescribed during pregnancy. There are some concerns as metformin crosses the placenta and effects on offspring exposed during pregnancy are unknown. Animal and human evidence indicate that metformin may create an atypical in-utero environment similar to under-nutrition which has been associated with adult obesity.... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/11/2024
Locations: Campbelltown Hospital, Campbelltown, New South Wales +11 locations
Conditions: Diabetes Mellitus, Type 2, Pregnancy in Diabetic, Child Obesity, Child Development
Register for Updates
Semaglutide and Vascular Regeneration
NCT05870462
Recruiting
SEMA-VR is a prospective, randomized, 6-month long, open-label study of semaglutide. Approximately 100 participants with type 2 diabetes and/or obesity will be randomized (1:1) to receive semaglutide at escalating doses (up to 1.0 mg/week) or usual care without semaglutide for 6 months. The goal of this trial is to understand how semaglutide exerts cardio-protective effects in people with type 2 diabetes and/or obesity. The main question it aims to answer is: • Does semaglutide treatment prese... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2023
Locations: North York Diagnostic and Cardiac Centre, North York, Ontario +1 locations
Conditions: Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Obesity
Register for Updates